Evaluation of quality assessment for CPXV vaccines.
<p>The Ramachandran plot assessment displays <b>(A)</b>. For CPVX-V1, 92.4% of the residues are located within favored regions, 6.3% in the allowed region, and 0.6% in the disallowed region. <b>(B)</b> For CPVX-V2, 90.8% of the residues are located within favored region...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852018795963482112 |
|---|---|
| author | Md. Mohaimenul Islam Tareq (21647527) |
| author2 | Sattyajit Biswas (21647530) Farazi Abinash Rahman (21647533) Labib Sharirar Siam (21647536) Sadia Jannat Tauhida (21647539) Shamim Ahmed (207438) Hasan Jafre Shovon (21647542) Mariya Ahmed (21647545) Kazi Afrin Jerin (21647548) Md. Nazmul Hasan (11525006) |
| author2_role | author author author author author author author author author |
| author_facet | Md. Mohaimenul Islam Tareq (21647527) Sattyajit Biswas (21647530) Farazi Abinash Rahman (21647533) Labib Sharirar Siam (21647536) Sadia Jannat Tauhida (21647539) Shamim Ahmed (207438) Hasan Jafre Shovon (21647542) Mariya Ahmed (21647545) Kazi Afrin Jerin (21647548) Md. Nazmul Hasan (11525006) |
| author_role | author |
| dc.creator.none.fl_str_mv | Md. Mohaimenul Islam Tareq (21647527) Sattyajit Biswas (21647530) Farazi Abinash Rahman (21647533) Labib Sharirar Siam (21647536) Sadia Jannat Tauhida (21647539) Shamim Ahmed (207438) Hasan Jafre Shovon (21647542) Mariya Ahmed (21647545) Kazi Afrin Jerin (21647548) Md. Nazmul Hasan (11525006) |
| dc.date.none.fl_str_mv | 2025-07-02T17:36:07Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pone.0326310.g003 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Evaluation_of_quality_assessment_for_CPXV_vaccines_/29461921 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biochemistry Medicine Microbiology Genetics Biotechnology Immunology Cancer Infectious Diseases Virology Biological Sciences not elsewhere classified three outer membrane term epitope visibility structural validation enabled quality 3d structures lumpy skin disease linked using aay discover possible targets certain distinctive features proteins &# 8217 xlink "> cpxv protein resolve a22 epitope vaccine constructions namely sheeppox virus developed vaccines might computational cloning analysis 122 cpxv proteins cell epitopes based extracellular proteins cell epitopes scaffold protein protein a35 v5 vaccine potential vaccine work used vipr database varied immunological solid foundation sheeppox ), several investigations results suggest quite safe practical settings physiochemical properties molecular weight molecular modeling molecular dynamics l12 adjuvants kk linkers immunoinformatic methodology huge socio gtpv ), grand average generate multi g activity economic effects docking scores comprehensive immunity cai value amino acids |
| dc.title.none.fl_str_mv | Evaluation of quality assessment for CPXV vaccines. |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>The Ramachandran plot assessment displays <b>(A)</b>. For CPVX-V1, 92.4% of the residues are located within favored regions, 6.3% in the allowed region, and 0.6% in the disallowed region. <b>(B)</b> For CPVX-V2, 90.8% of the residues are located within favored regions, 5.3% in the allowed region, and 1.5% in the disallowed region. <b>(C)</b> For CPVX-V5, 90.5% of the residues are located within favored regions, 6.2% in the allowed region, and 0.7% in the disallowed region. <b>(D)</b> For CPVX-V4, 89.7% of the residues are located within favored regions, 7.7% in the allowed region, and 0.7% in the disallowed region. <b>(E)</b> For CPVX-V3, 93.1% of the residues are located within favored regions, 4.6% in the allowed region, and 0.6% in the disallowed region.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_e50a1dc5ef8d2a5cfc0afe30eebc2bd6 |
| identifier_str_mv | 10.1371/journal.pone.0326310.g003 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/29461921 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Evaluation of quality assessment for CPXV vaccines.Md. Mohaimenul Islam Tareq (21647527)Sattyajit Biswas (21647530)Farazi Abinash Rahman (21647533)Labib Sharirar Siam (21647536)Sadia Jannat Tauhida (21647539)Shamim Ahmed (207438)Hasan Jafre Shovon (21647542)Mariya Ahmed (21647545)Kazi Afrin Jerin (21647548)Md. Nazmul Hasan (11525006)BiochemistryMedicineMicrobiologyGeneticsBiotechnologyImmunologyCancerInfectious DiseasesVirologyBiological Sciences not elsewhere classifiedthree outer membraneterm epitope visibilitystructural validation enabledquality 3d structureslumpy skin diseaselinked using aaydiscover possible targetscertain distinctive featuresproteins &# 8217xlink "> cpxvprotein resolve a22epitope vaccine constructionsnamely sheeppox virusdeveloped vaccines mightcomputational cloning analysis122 cpxv proteinscell epitopes basedextracellular proteinscell epitopesscaffold proteinprotein a35v5 vaccinepotential vaccinework usedvipr databasevaried immunologicalsolid foundationsheeppox ),several investigationsresults suggestquite safepractical settingsphysiochemical propertiesmolecular weightmolecular modelingmolecular dynamicsl12 adjuvantskk linkersimmunoinformatic methodologyhuge sociogtpv ),grand averagegenerate multig activityeconomic effectsdocking scorescomprehensive immunitycai valueamino acids<p>The Ramachandran plot assessment displays <b>(A)</b>. For CPVX-V1, 92.4% of the residues are located within favored regions, 6.3% in the allowed region, and 0.6% in the disallowed region. <b>(B)</b> For CPVX-V2, 90.8% of the residues are located within favored regions, 5.3% in the allowed region, and 1.5% in the disallowed region. <b>(C)</b> For CPVX-V5, 90.5% of the residues are located within favored regions, 6.2% in the allowed region, and 0.7% in the disallowed region. <b>(D)</b> For CPVX-V4, 89.7% of the residues are located within favored regions, 7.7% in the allowed region, and 0.7% in the disallowed region. <b>(E)</b> For CPVX-V3, 93.1% of the residues are located within favored regions, 4.6% in the allowed region, and 0.6% in the disallowed region.</p>2025-07-02T17:36:07ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pone.0326310.g003https://figshare.com/articles/figure/Evaluation_of_quality_assessment_for_CPXV_vaccines_/29461921CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/294619212025-07-02T17:36:07Z |
| spellingShingle | Evaluation of quality assessment for CPXV vaccines. Md. Mohaimenul Islam Tareq (21647527) Biochemistry Medicine Microbiology Genetics Biotechnology Immunology Cancer Infectious Diseases Virology Biological Sciences not elsewhere classified three outer membrane term epitope visibility structural validation enabled quality 3d structures lumpy skin disease linked using aay discover possible targets certain distinctive features proteins &# 8217 xlink "> cpxv protein resolve a22 epitope vaccine constructions namely sheeppox virus developed vaccines might computational cloning analysis 122 cpxv proteins cell epitopes based extracellular proteins cell epitopes scaffold protein protein a35 v5 vaccine potential vaccine work used vipr database varied immunological solid foundation sheeppox ), several investigations results suggest quite safe practical settings physiochemical properties molecular weight molecular modeling molecular dynamics l12 adjuvants kk linkers immunoinformatic methodology huge socio gtpv ), grand average generate multi g activity economic effects docking scores comprehensive immunity cai value amino acids |
| status_str | publishedVersion |
| title | Evaluation of quality assessment for CPXV vaccines. |
| title_full | Evaluation of quality assessment for CPXV vaccines. |
| title_fullStr | Evaluation of quality assessment for CPXV vaccines. |
| title_full_unstemmed | Evaluation of quality assessment for CPXV vaccines. |
| title_short | Evaluation of quality assessment for CPXV vaccines. |
| title_sort | Evaluation of quality assessment for CPXV vaccines. |
| topic | Biochemistry Medicine Microbiology Genetics Biotechnology Immunology Cancer Infectious Diseases Virology Biological Sciences not elsewhere classified three outer membrane term epitope visibility structural validation enabled quality 3d structures lumpy skin disease linked using aay discover possible targets certain distinctive features proteins &# 8217 xlink "> cpxv protein resolve a22 epitope vaccine constructions namely sheeppox virus developed vaccines might computational cloning analysis 122 cpxv proteins cell epitopes based extracellular proteins cell epitopes scaffold protein protein a35 v5 vaccine potential vaccine work used vipr database varied immunological solid foundation sheeppox ), several investigations results suggest quite safe practical settings physiochemical properties molecular weight molecular modeling molecular dynamics l12 adjuvants kk linkers immunoinformatic methodology huge socio gtpv ), grand average generate multi g activity economic effects docking scores comprehensive immunity cai value amino acids |